Research programme: metabotropic glutamate receptor modulators - AstraZeneca

Drug Profile

Research programme: metabotropic glutamate receptor modulators - AstraZeneca

Alternative Names: CPPZ; NPS 2398; NPS-2390

Latest Information Update: 21 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; NPS Pharmaceuticals
  • Developer AstraZeneca; National Institute on Drug Abuse
  • Class Quinoxalines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators; Metabotropic glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; CNS disorders; Drug abuse; Epilepsy; Pain; Schizophrenia; Stroke

Most Recent Events

  • 21 Aug 2013 AstraZeneca is collaborating with the National Institute on Drug Abuse for the development of a metabotropic glutamate receptor modulator in Drug abuse
  • 13 Aug 2013 Preclinical trials in Drug abuse in USA (unspecified route)
  • 13 Nov 2010 Preclinical trials in Schizophrenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top